Download TP1. Indicative topics

The Sixth RTD Framework
Programme 2002-2006
Thematic Priority 1
Life Sciences: Genomics &
Biotechnology for Health
http://europa.eu.int/comm/research/fp6/index_en.html
http://www.cordis.lu/fp6/
Focussing and integrating Community
research: 7 Thematic priorities
Budget (million € )
1. Life sciences: genomics & biotechnology
for health
2. Information society technologies
3. Nanotechnologies & nanosciences….
4. Aeronautics & space
5. Food quality & safety
6. Sustainable development, global change
and ecosystems
7. Citizens and governance….
2,255
3,625
1,300
1,075
685
2,120
225
TP1. Life sciences: genomics &
biotechnology for health
Why focus on genomics ?
 Sequencing of human genome (and other genomes)
 Major opportunity to improve human health
 Stimulus for business activity
 Needs to transform mass of raw data into useful
knowledge
 To be competitive with US and Japan, we need to have
a coordinated approach at the European level for many
topics in genomics.
 EU will invest by scientific interest and for avoiding to
become a “client”
Integration with other approaches  Multidisciplinarity
TP1. Life sciences: genomics &
biotechnology for health
First call expected 17 December 2002
Deadline 25 March 2003
Thematic priority 1.
First call & Work programme
Illustrations only!
focusing on Networks of Excellence and
Integrated Projects
TP1. Life sciences: genomics &
biotechnology for health
Funding instruments
New (inclusion of new partners during project life-time)
- Networks of Excellence
- Integrated Projects
“Traditional”
- Specific Targeted Research Projects (STREP)
- Co-ordination actions (CA)
- Specific Support Actions (SSA)
Also don’t miss other opportunities (including fellowships)
across the whole Sixth Framework Programme!
TP1. First call: indicative budget
Total budget for first call: € 513 million,
broken down as follows:
Instrument
€ (million)
Integrated project or network of excellence 385 – 410
Specific targeted research project or
co-ordination action
Specific support actions
92 – 121
8 – 10
TP1. First call: indicative budget
15% of FP Thematic Priorities budget is for
participation of small and medium sized enterprises
(SMEs)
Specific activities
‘Co-operative research’: carried out by research centres for SMEs
or by high- tech SMEs in collaboration with research centres and
universities
‘Collective research’: carried out by research centres for industrial
associations or industry groupings in entire sectors of industry
dominated by SMEs
TP1. Life sciences: genomics &
biotechnology for health
i. Advanced genomics and its applications for health
(€ 1,100 m)
a. Fundamental knowledge and basic tools for functional
genomics in all organisms
(FP5: Generic Activities, Research into Genomes and diseases of
genetic origin)
b. Application of knowledge and technologies in the field
of genomics and biotechnology for health
(FP5: Key Action 3, The “Cell Factory”
TP1. Life sciences: genomics &
biotechnology for health
ii. Combating major diseases (€ 1,155 m)
a. Applications- oriented genomic approaches to
medical knowledge and technologies
(FP5: GA 7-Chronic and degenerative diseases, diabetes,
cardiovascular diseases and rare diseases, GA9-Neurosciences,
KA6-Ageing population)
b. Combating cancer (FP5: GA7)
c. Confronting the major communicable diseases
linked to poverty (AIDS, tuberculosis, malaria)
(FP5: KA2 Control of Infectious Diseases)
TP1. Life sciences: genomics &
biotechnology for health
Expressions of Interest
Report on the analysis of expressions of interest 2002
Thematic priority 1
“Genomics and biotechnology for health”
http://www.cordis.lu/fp6/eoi-analysis.htm
>Potential topics that could be used for first and
subsequent calls of FP6
>To help potential participants become familiar with the
new instruments
TP1. Life sciences: genomics
& biotechnology for health
i. Advanced genomics and
its applications for health
a. Fundamental knowledge and basic tools for
functional genomics in all organisms
to foster basic understanding of genomic information, by
developing the knowledge base, tools and resources needed to
decipher the function of genes and gene products relevant to
human health
- Gene expression and proteomics
- Structural genomics
- Comparative genomics and population genetics
- Bioinformatics
- Multidisciplinary functional genomics approaches
to basic biological processes
TP1. Indicative topics/
instruments for first call
Gene expression and proteomics
(2 topics in first call) (1 indicative topic for next call(s))
Developing high throughput tools and approaches for monitoring
gene expression and protein profiles and for determining protein
function and protein interactions
• Development of advanced array technologies
(IP/NoE)
- for the analysis, with high precision and sensitivity,
of large sets of proteins, DNA and RNA and for
functional cell arrays
Technology development
TP1. Indicative topics/
instruments for first call
Structural genomics (3) (2)
Developing high throughput approaches for determining
high-resolution 3-D structures of macromolecules.
• Development of new hardware and software for the
implementation of innovative automated technologies at
synchrotron sites (IP)
- developing, assembling, standardising and providing
highly integrated and automated technological platforms
at synchrotron research centres for high throughput
structural genomics
Specific and ambitious objectives
Infrastructures can be part of IP and NoE
TP1. Indicative topics/
instruments for first call
Comparative genomics and population
genetics (2) (4)
Developing model organisms and transgenic tools; developing
epidemiology tools and standardised genotyping protocols.
• Integrated tools for functional genomics of nonmammalian vertebrate models for human development
and disease mechanisms (IP)
- develop and use high throughput tools, technologies
and approaches …. for harvesting large data sets on
gene functions...
Model organisms: to complement the ‘integrated
project’ on mouse functional genomics (funded by the
QoL programme in FP5)
TP1. Indicative topics/
instruments for first call
Bioinformatics (1) (2)
Developing bioinformatics tools and resources for data storage,
mining and processing; developing computational biology approaches for
in silico prediction of gene function and for the simulation of complex
regulatory networks.
• Developing methods and resources in bioinformatics
to focus on the annotation of human and other
genomes (NoE)
- cooperation between life scientists and
bioinformaticians to coordinate … the design and
development of new integrated bioinformatics tools
and approaches...
Structuring the field - life scientists & bioinformaticians
Spreading excellence
TP1. Indicative topics/
instruments for first call
Multidisciplinary functional genomics
approaches to basic biological processes (7) (8)
Elucidation of the mechanisms underlying fundamental
cellular processes, to identify the genes involved and to decipher
their biological functions in living organisms.
• Integrated comparative and functional genomics
approaches for studying the cell cycle (IP/ NoE)
- multidisciplinary functional genomics approaches in
different model organisms for elucidating .. Basic
mechanisms controlling the cell cycle
Basic knowledge - wide implications in health research
TP1. Indicative topics/
instruments for first call
Multidisciplinary functional genomics approaches to
basic biological processes (continued)
• Multidisciplinary approaches of functional genomics
to study chronic inflammation processes in human
disease (NoE)
- co-ordination of research activities …
Specific diseases can be addressed ..but the emphasis
should be on basic mechanisms
Basic mechanisms - implications in many diseases
TP1. Indicative topics/
instruments for first call
Research areas - 1st call - STREP/CA/SSA
• transcription activation, signal transduction, intracellular communication, the role of non-coding genomic
information, mechanisms of integration of genes
• in silico prediction of gene function and simulation of
complex regulatory networks
• development of new tools and approaches, including
the standardisation of protocols, to facilitate generation
of new knowledge in functional and structural genomics
TP1. Indicative topics/
instruments for first call
1. Advanced genomics and its applications to health
b. Applications of knowledge and technologies in the
field of genomics and biotechnology for health
• to foster the competitiveness of Europe’s
biotechnology industry
• the integration of small and medium sized
enterprises (SMEs) in projects is essential
TP1. Indicative topics/
instruments for first call
Technological platforms for developments in the fields
of new diagnostic, prevention and therapeutic tools
- New, safer, more effective drugs, pharmacogenomics
approaches (4) (3)
- New diagnostics (1) (2)
- New in vitro tests to replace animals (1) (1)
- New preventive and therapeutic tools (e.g. stem cells,
immunotherapies) (3) (6)
- Innovative post-genomic research with high potential
for application (2) (4)
TP1. Indicative topics/
instruments for first call
New, safer, more effective drugs,
pharmacogenomics approaches (4)(3)
translation of the knowledge and methods derived from
genomics into concrete applications for drug design and
development
• Genome-based individualised medicines (NoE)
- structuring of efforts devoted to characterisation of
drug targets.. to optimise individual drug selection,
dosage and delivery .. to improve the benefit / risk
ratio of drugs
Cooperation of research and clinical centres, ethical
bodies, regulatory authorities, healthcare providers,
pharmaceutical industry
TP1. Indicative topics/
instruments for first call
New diagnostics (1)(2)
early diagnosis, monitoring of disease progression
and interpretation of in-vivo data
• Non-invasive diagnostics and diagnostic procedures;
development of markers for ante- and neo-natal
screening (NoE)
- structuring of efforts devoted to development of noninvasive tools for pre-natal diagnosis and the
translation of genomics data into diagnostic
applications….
Translational research; cooperation of academia,
ethical bodies, regulatory authorities, pharmaceutical
industry
TP1. Indicative topics/
instruments for first call
New in vitro tests to
replace animal experimentation (1)(1)
Directive 86/609/EEC regarding the protection of
animals used for experimental and other scientific purposes
• Combination and application of in vitro cell and
sensor technologies in the field of animal in vivo
toxicology (IP)
- research should focus on in vitro cell-based
toxicological and pharmacological tests for screening
drug compounds
Technology development
TP1. Indicative topics/
instruments for first call
New preventative and therapeutic tools (3)(6)
integration of different research activities in genetics,
fundamental and clinical research and ethics to provide
standardised research materials such as stem cell banks, clinical
research protocols and novel preventive and therapeutic
instruments at a European level.
• New advances in cell-based therapies for the
regeneration of connective tissue (IP)
- application of mesenchymal stem cell research, gene
transfer and tissue engineering for the treatment of
connective tissue diseases….. defining quality and
safety standards for tissue regeneration ... leading to
new biological implants capable of functional load
bearing
Several disciplines involved
Industry, regulatory authorities
TP1. Indicative topics/
instruments for first call
Post-genomics with high application potential (2)(4)
use cutting edge technologies in a multidisciplinary
approach to address areas of research that will benefit from the
developments resulting from genomics
• Plant platforms for immunotherapeutic biomolecule
production (IP)
- focus on pharmaceuticals (vaccines, other
immunotherapeutics) for which a plant-based
production system offers real advantage and potential
Appropriate participation of developing countries
Experimental design to minimise ecological impact
TP1. Indicative topics/
instruments for first call
Research areas - 1st call - STREP/CA/SSA
New drugs targeting G-protein coupled receptors through
pharmacogenomics
Educational schemes utilising interdisciplinary approaches
for the integration of pre-clinical and clinical research (e.g.
training events, workshops)
Development of novel non-invasive and repeatable diagnostics
using bioinformatic tools
New diagnostic tools for prion associated diseases
TP1. Indicative topics/
instruments for first call
Research areas - 1st call - STREP/CA/SSA
Technology foresight meeting on test development, validation
and implementation
Workshop on business opportunities in pharmaceutical
toxicology
Partnership event on the development and manufacture of
toxicology test methods for regulatory testing needs
Forum on the achievements in raising awareness on the use of
alternative methods in Candidate Countries
TP1. Life sciences: genomics &
biotechnology for health
ii. Combating major diseases
a. Applications- oriented genomic approaches to
medical knowledge and technologies
- Cardiovascular disease, diabetes, rare diseases
- Resistance to antibiotics and other drugs
- Brain and combating diseases of the nervous system
- Human development and the ageing process
TP1. Life sciences: genomics &
biotechnology for health
ii. Combating major diseases
a. Applications- oriented genomic approaches to
medical knowledge and technologies
•
to develop improved strategies for the prevention and
management – using also advanced technologies for health - of
human disease and for living and ageing healthily
•
integrate a genomic approach through all relevant organisms into
more established medical approaches for investigating disease
and health determinants
•
translational research aimed at bringing basic knowledge through
to clinical application
TP1. Indicative topics/
instruments for first call
Cardiovascular, diabetes, rare diseases (6)(4)
> Integrating clinical expertise and resources with relevant
model systems and advanced tools in functional genomics
==>> breakthroughs in prevention and disease management
> Pool Europe’s research resources to tackle rare diseases
• Genomics of heart muscle development and disease
(NoE)
- durable integration of researchers working on normal/abnormal development of the heart… translation
of new knowledge to the treatment of complications
of heart disease (heart failure, arrhythmias)
Child health: congenital cardiovascular malformation
TP1. Indicative topics/
instruments for first call
Resistance to antibiotics and other drugs (2)(4)
> Exploitation of knowledge of microbial genomes and hostpathogen interactions ==>> vaccines, alternative strategies;
> Strategies for optimal use of antimicrobials
> Support EC network on epidemiological surveillance and
control of communicable diseases.
• Testing anti-viral drug resistance and understanding
resistance development (IP or NoE)
- setting up a broad approach towards testing and
following up antiviral drug resistance in human virus
infections…. integrate basic, clinical,
pharmacological, immunological and virological
research
TP1. Indicative topics/
instruments for first call
Brain, combating diseases of the nervous system (6)(5)
use genome information to understand better brain function,
damage, plasticity and repair, learning, memory, cognition in
order to gain new insight into mental processes, to combat
neurological disorders and diseases, and to improve brain
repair
• Human brain tissue research (NoE)
- research and studies on genetic and environmental
influences on brain diseases
- standardisation of tissue sampling, shared use,
diagnosis, ethical issues, clinical history, genotyping,
accessibility and training
Infrastructural aspects, structuring the field
Spreading excellence
TP1. Indicative topics/
instruments for first call
Human development and the ageing process (2)(4)
Human genome sequence, genomic and postgenomic research
applied to understand human development and healthy ageing
in order to develop the evidence base for improving public
strategies and to promote healthy living and healthy ageing
• Genetic factors of longevity and healthy ageing
(IP/NoE)
- to compare health status, family history, different age
and gender groups, genetic background to identify
genetic markers and expression profiles for the
prediction of … longevity and healthy ageing
Population studies, special expertise and facilities in
Europe
TP1. Indicative topics/
instruments for first call
Research areas - 1st call - STREP/CA/SSA
Rare disorders of plasma membrane transporters for aminoacids, lipids and sugars
Workshop on the structuring of European research activities
to more effectively combat drug resistant hospital infections
Specific brain research support actions
Molecular mechanisms of bone homeostasis - prevention or
treatment of osteoporosis
TP1. Indicative topics/
instruments for first call
ii. Combating major diseases
b. Combating cancer (6) (8)
Establishing facilities for exploitation of research (evidence-based
guidelines for good clinical practice and improved public health
strategies), supporting clinical research/clinical trials, supporting
translational reseach
• Translating basic knowledge of functional oncogenomics into cancer diagnosis and treatment (IP/NoE)
large-scale analysis to identify signalling pathways,
oncogenes, tumour supressor genes
- epigenetic mechanisms and genomic instability
- new molecular targets for anticancer drug discovery
-
Translational research
TP1. Indicative topics/
instruments for first call
ii. Combating major diseases
c. Confronting the major communicable
diseases linked to poverty (5) (5)
Developing candidate interventions, establishing a clinical trials
programme, establishing an AIDS Therapy Trials Network
- HIV/AIDS
- malaria
- tuberculosis
Also: European and Developing Countries Clinical Trials
Partnership (EDCTP) - action through Treaty Article 169
TP1. Indicative topics/
instruments for first call
Additional SSAs to be supported:
Promotion of SME participation
Stimulating international co-operation
Linking with Candidate Countries
Stimulating exploitation: of research results
stemming from past and present EU programmes
Realising ERA objectives: activities such as pilot
initiatives on benchmarking, cartography, networking,
the debate on human values and technology options,
or the collective management of the knowledge
infrastructures of the future, etc
EU Strategy for Life Sciences and Biotechnology.
Action Plan attached to COM(2002)27
Supporting future research policy development
TP1. First call
EC contribution ?
Integrated project
Rough estimate: € 10-15 million - but higher possible
(compare QoL integrated projects in FP5)
http://europa.eu.int/comm/research/fp6/pdf/ip_provisions_111102f
inal.pdf
Network of excellence (examples)
100 researchers, 25 PhD students
ca € 10.5 million
200 researchers, 50 PhD students
ca € 18.5 million
http://europa.eu.int/comm/research/fp6/pdf/noe_111102final.pdf
TP1. First call
How many integrated projects/ network of excellence
will be funded for the first call in TP1?
53 topics to be published in the call
Budget available for IP or NoE € 385 – 410 million
Therefore, competition between proposals for the
same topic, as well as between topics
Some topics may not be funded
TP1. First call
Indicative schedule
First call published : 17 December 2002
First deadline : (25) March 2003
Other tentative deadlines :
November 2003
November 2004
November 2005
Other FP6 actions
related to Life Sciences (health)
“ERA-NET”
•Supporting the cooperation and coordination of research
activities carried out at national or regional level
•Health of key groups (major diseases, rare diseases,
poverty-related diseases, alternative/non-conventional
medicine)
http://europa.eu.int/comm/research/fp6/era-net.html
http://europa.eu.int/comm/research/fp6/pdf/11385-2_en.pdf
Other FP6 actions
related to Life Sciences (health)
Anticipating science and technology needs
(“Priority 8” - FP5: GA10-11)
>Research responding to health policy requirements:
• implementation of the European Social Agenda
•
public health and consumer protection
>Health determinants, provision of high quality and
sustainable health care services (ageing, demographic
change)
>Public health issues, including epidemiology for
disease prevention
>Impact of environmental issues on health
>Handicapped / disabled people
Other FP6 actions
related to Life Sciences (health)
TP2. Information society technologies
bioinformatics; data handling; communication
TP3. Nanotechnologies … nanobiotechnology; clean
technologies; nanodevices for drug delivery; biosensors; tissue
regeneration; biomaterials (FP5: Growth and QoL KA3)
TP5. Food quality and safety
nutrition; plant and animal
biotech; food diseases and allergies; GMO traceability; functional
food; pathogenic microorganisms; BSE (FP5: QoL KA1 & 4)
TP6. Sustainable development and global change
renewable energies; marine and terrestrial biodiversity and
ecosystems (FP5: EESD)
TP1. Life sciences: genomics &
biotechnology for health
Further Information
Fundamental genomics:
[email protected]
Applied genomics & biotech:
[email protected]
Major diseases:
[email protected]
Cancer:
[email protected]
Poverty related diseases:
[email protected]
Research related to structuring / strengthening ERA:
[email protected]